QDTE’s weekly distributions fell to $0.19 per share in 2026 from $0.35 in 2024 due to lower volatility and option premiums. The Roundhill Innovation-100 0DTE Covered Call Strategy ETF (QDTE) has seen its weekly distributions decline to $0.19 per share in 2026, down from an
Bank cuts year-end silver price outlook after January’s 27% plunge and weakening industrial demand. JPMorgan reduced its silver price forecast to $60-$65 an ounce for the remainder of 2026, down from a prior estimate of $81. The revision follows a 27% crash in January afte
The NEOS S&P 500 High Income ETF delivers monthly distributions at a 12% annualized yield without significant share price decline. The NEOS S&P 500 High Income ETF (SPYI) has grown to $6.9 billion in assets, offering a 12% annualized yield through monthly distributions at
Quick Read - IEMG attracted $22 billion in new investor money over 12 months, a figure more than double VWO's inflows, and returned 33% versus VWO's 20%. - South Korea's MSCI emerging market status puts Samsung and SK Hynix in IEMG's top 3 holdings, while VWO excludes both...
Quick Read - NVDA earns a Buy as its forward P/E compresses to 23 despite 85% revenue growth, while AAPL holds at a premium valuation. - GOOG earns a Buy at a forward P/E of 25 as Google Cloud surges 63% and Search grows 19%, defusing the AI-kills-Search thesis. - The three most...</stron
Analyst lowers TransMedics Group target amid stable MedTech sector trends while company expands European organ transplant logistics. Evercore ISI analyst Daniel Markowitz reduced the price target on TransMedics Group (NASDAQ:TMDX) to $90 from $100, maintaining an Outperfor
The fund's distribution climbs 10.5% week-over-week, lifting its annualized yield to 42.05%. YieldMax’s BABA Option Income Strategy (BABO) declared a weekly distribution of $0.0600, up 10.5% from last week’s $0.0543. The move lifts the fund’s annualized distribution rate t
Analyst firm lowers PODD target amid sector-wide MedTech trends while company expands Omnipod 5 in Spain. Evercore ISI reduced its price target on Insulet Corporation (NASDAQ:PODD) to $180 from $200, maintaining an Outperform rating. The adjustment was part of the firm’s s
H.C. Wainwright raises Ionis Pharmaceuticals' price target to $130 following FDA approval of its RNA-targeted therapy Tryngolza. H.C. Wainwright increased its price target on Ionis Pharmaceuticals (NASDAQ:IONS) to $130 from $125, maintaining a Buy rating. The adjustment fo
HSBC lowered its price target on Regeneron Pharmaceuticals while maintaining a Buy rating amid a broader healthcare sector review. HSBC reduced its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) to $800 from $990, reaffirming a Buy rating on the stock. The adjust
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.